Venus Concept INC 8-K filings

Venus Concept Inc. has secured waivers for minimum liquidity requirements and extended its bridge loan maturity date to February 13, 2026, while drawing an additional $2 million for working capital.

Venus Concept Inc. announced its voluntary delisting from Nasdaq and deregistration with the SEC, alongside securing short-term waivers for loan liquidity requirements and a brief extension of its bridge loan maturity date.

Venus Concept Inc. obtained waivers for liquidity requirements and extended a bridge loan maturity date, converting an upcoming interest payment to principal.

Venus Concept Inc. has secured critical amendments to its loan agreements, extending maturity dates and waiving liquidity requirements through December 31, 2025, while also receiving a $1.5 million bridge loan drawdown.

Venus Concept Inc. reported an increased net loss for the third quarter of 2025, alongside the significant announcement of FDA clearance for its new multi-application Venus NOVA platform.

Venus Concept Inc. announced a consent agreement for its Main Street Priority Loan, a twenty-first amendment to its Bridge Loan extending maturity, and a new $2 million drawdown for working capital.

Venus Concept Inc. reduced its debt by $11.48 million through a debt-to-equity exchange with Madryn, extended its Bridge Loan maturity, and increased its delayed draw commitment.

Venus Concept Inc. announced a new $2 million drawdown from its bridge financing facility and approved transaction completion bonuses for two key executives contingent on a strategic transaction.

Venus Concept Inc. obtained waivers for minimum liquidity requirements and extended a bridge loan maturity date to September 30, 2025, from its lenders.

Venus Concept Inc. announced it has secured an additional $2 million in bridge financing from Madryn Health Partners for general working capital.

Venus Concept Inc. reported a 5% year-over-year revenue decline to $15.7 million in Q2 2025, alongside strategic debt reduction and a planned $20 million asset sale.

Venus Concept Inc. has amended its bridge loan agreement, significantly increasing its delayed draw term loan capacity to $21 million and extending the maturity date to August 31, 2025.

Venus Concept Inc. has secured multiple short-term extensions and liquidity waivers for its loan and note agreements, alongside an amendment to its preferred stock terms.

Venus Concept Inc. announced the drawdown of an additional $2 million from its existing high-interest bridge financing facility, bringing the total drawn to over $19.2 million.

Venus Concept Inc. announced a $6.5 million debt-to-equity exchange with Madryn Health Partners, significantly reducing its outstanding debt and optimizing its capital structure while securing crucial liquidity waivers and loan extensions.

Venus Concept Inc. announced that its stockholders approved the election of Class II Directors and the issuance of common stock upon the conversion of various preferred stock series and convertible notes at its Annual and Special Meeting held on June 25, 2025.

Venus Concept Inc. has successfully closed a registered direct offering and concurrent private placement, raising $1.15 million upfront with potential for an additional $2.3 million from warrant exercises, to fund working capital and general corporate purposes.

Venus Concept Inc. announced it has entered into a definitive agreement to sell its Venus Hair Business, including ARTAS and NeoGraft technologies, to MHG Co., Ltd. for $20 million in cash, with the transaction expected to close in Q3 2025.

Venus Concept Inc. has obtained critical short-term waivers for minimum liquidity requirements and extended a bridge loan maturity by only one month, while also opting to pay interest in kind, signaling severe and ongoing financial challenges.

Venus Concept Inc. announced it has secured an additional $2 million drawdown under its existing bridge financing agreement with Madryn Health Partners, bringing the total facility to over $23 million at a 12% interest rate.

Venus Concept's Q1 2025 revenue declined 22% year-over-year to $13.6 million, reflecting ongoing market difficulties, while the company focuses on cost management and strategic alternatives.

Venus Concept Inc. announces agreements with lenders to waive liquidity requirements and extend the maturity date of a bridge loan, providing short-term financial relief.

Venus Concept Inc. has entered into agreements for a registered direct offering of common stock, expected to close on April 14, 2025, to raise approximately $1.57 million.

Venus Concept Inc. files an amendment to its previous 8-K report to correct the form of the Placement Agent Warrant issued to H.C. Wainwright & Co., LLC in connection with a registered direct offering.

Venus Concept Inc. has entered into agreements for a registered direct offering of 328,573 shares of common stock at $3.50 per share, raising approximately $1.1 million.

Venus Concept Inc. has obtained $2 million in financing through an eighth drawdown from its existing loan agreement with Madryn Health Partners.

Venus Concept reduces debt by $11 million through an exchange with Madryn Asset Management, converting subordinated convertible notes into Series Y preferred stock.

Venus Concept announced its Q4 and fiscal year 2024 financial results, highlighting a reduction in debt and operational cash use, alongside an amendment to its Bridge Loan Agreement for additional financing.

Venus Concept Inc. announces amendments to its loan agreements with Madryn Health Partners, including waivers on liquidity requirements and an extension of the bridge loan maturity date.

Venus Concept announces extensions to debt maturity dates and a 1-for-11 reverse stock split to maintain Nasdaq listing.